PITTSBURGH, Dec. 17, 2021 /PRNewswire/ -- Viatris Inc.
(NASDAQ: VTRS) today announced that it will move its investor event
previously scheduled for Friday, January 7,
2022 to no later than February 28,
2022 in conjunction with the release of its fourth quarter
2021 results. The Company also reiterated its 2021 financial
guidance, previously provided on November 8,
2021.
At its investor event, the Company will provide additional
detail on its two-phased strategic roadmap, including:
- For the rest of Phase I—2022 and 2023—the Company will provide
specific financial guidance, targets and metrics to complete this
phase. The Company will also discuss the substantial cash flows
that will be generated over this period to satisfy Phase I capital
allocation priorities of returning capital to shareholders and
repaying $6.5 billion of debt.
- For Phase II—2024 and beyond—the Company will provide an
overview of the catalysts that are expected to drive future growth
including laying out the Company's capital allocation priorities
for this phase to maximize and further unlock shareholder value
during this period. The Company will also be giving specific
details of its pipeline and will be providing the inorganic
business development priorities the Company will be focusing on
through its Global Healthcare Gateway®.
About Viatris
Viatris Inc. (NASDAQ: VTRS) is a new kind of healthcare
company, empowering people worldwide to live healthier at every
stage of life. We provide access to medicines, advance sustainable
operations, develop innovative solutions and leverage our
collective expertise to connect more people to more products and
services through our one-of-a-kind Global Healthcare Gateway®.
Formed in November 2020, Viatris
brings together scientific, manufacturing and distribution
expertise with proven regulatory, medical and commercial
capabilities to deliver high-quality medicines to patients in more
than 165 countries and territories. Viatris' portfolio comprises
more than 1,400 approved molecules across a wide range of
therapeutic areas, spanning both non-communicable and infectious
diseases, including globally recognized brands, complex generic and
branded medicines, a growing portfolio of biosimilars and a variety
of over-the-counter consumer products. With a global workforce of
approximately 38,000, Viatris is headquartered in the
U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at
viatris.com and investor.viatris.com, and connect with us on
Twitter
at @ViatrisInc, LinkedIn and YouTube.
Forward-Looking Statements
This press release includes
statements that constitute "forward-looking statements." These
statements are made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Such forward
looking statements may include statements that Viatris will move
its investor event previously scheduled for Friday, January 7, 2022 to no later than
February 28, 2022 when the Company
expects to report its fourth quarter 2021 results; that the Company
reiterated its 2021 financial guidance, previously provided on
November 8, 2021; that the Company
will provide additional details on its two-phased strategic
roadmap; for Phase I, the Company will provide specific financial
guidance, targets and metrics, and will also discuss the
substantial cash flows that will be generated over this period to
satisfy Phase I capital allocation priorities of returning capital
to shareholders and repaying $6.5
billion of debt; and for Phase II, the Company will provide
an overview of the catalysts that are expected to drive future
growth including laying out the Company's capital allocation
priorities for this phase to maximize and further unlock
shareholder value during this period, and will also be giving
specific details of its pipeline and will be providing the
inorganic business development priorities the Company will be
focusing on through its Global Healthcare Gateway®. Because
forward-looking statements inherently involve risks and
uncertainties, actual future results may differ materially from
those expressed or implied by such statements. Factors that could
cause or contribute to such differences include, but are not
limited to: the potential impact of public health outbreaks,
epidemics and pandemics, including the ongoing challenges and
uncertainties posed by the COVID-19 pandemic; the integration of
Mylan N.V. and Pfizer Inc.'s Upjohn business (the "Upjohn
Business"), which combined to form Viatris (the "Combination") and
the implementation of our global restructuring initiatives being
more difficult, time consuming or costly than expected, or being
unsuccessful; the ability to achieve expected benefits, synergies
and operating efficiencies in connection with the Combination or
its restructuring initiatives within the expected timeframe or at
all; actions and decisions of healthcare and pharmaceutical
regulators; changes in healthcare and pharmaceutical laws and
regulations in the U.S. and abroad; any regulatory, legal or other
impediments to Viatris' ability to bring new products to market,
including but not limited to "at-risk" launches; Viatris' or its
partners' ability to develop, manufacture and commercialize
products; the scope, timing and outcome of any ongoing legal
proceedings and the impact of any such proceedings; any significant
breach of data security or data privacy or disruptions to our
information technology systems; risks associated with international
operations, including our operations in China; the ability to protect intellectual
property and preserve intellectual property rights; changes in
third-party relationships; the effect of any changes in Viatris' or
its partners' customer and supplier relationships and customer
purchasing patterns; the impacts of competition; changes in the
economic and financial conditions of Viatris or its partners;
uncertainties and matters beyond the control of management; and the
other risks Viatris' filings with the Securities and Exchange
Commission. Viatris routinely uses its website as a means of
disclosing material information to the public in a broad,
non-exclusionary manner for purposes of the SEC's Regulation Fair
Disclosure (Reg FD). Viatris undertakes no obligation to update
these statements for revisions or changes after the date of this
release other than as required by law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/viatris-to-move-its-investor-event-previously-scheduled-for-january-7-to-no-later-than-february-28-when-the-company-expects-to-report-its-fourth-quarter-2021-results-301447700.html
SOURCE Viatris Inc.